Showing 41-50 of 372 results for "".
- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions. A special configuration of Candela's Alex TriVantage platform tha…
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President, Research and Development and Chief…
- Foamix, Ltd. Will Present Phase II Results for Topical Minocycline at Upcoming Conferencehttps://practicaldermatology.com/news/20140227-foamix_ltd_will_present_phase_2_results_for_topical_minocycline_at_upcoming_conference/2459328/Foamix will present the successful results from its Phase II clinical trials with topical minocycline for acne and impetigo at the 34th Annual Cowen & Company Health Care Conference. The pharmaceutical company, which focuses on the development of patented topical foams for dermatology, announced t…
- Scioderm Initiates Phase IIB Study of SD-101 to Treat Epidermolysis Bullosahttps://practicaldermatology.com/news/20140107-scioderm_initiates_phase_iib_study_of_sd-101_to_treat_epidermolysis_bullosa/2459377/A Phase IIB study to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), was initiated, according to Scioderm, Inc. The Phase IIB study (SD-003) is a multi-site, prospective…
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median o…
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel Pharmaceuticals Limited. Independent Data Safety Monitoring Board stated…
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe plaque psoriasis. These new results were presented at the 22nd Congress of the Europe…
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A392111…
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 …
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III can also be used in a wide range of other body shaping applications such as cellulite treatments. "In…